Creating Value Through Breakthrough Science

We invest in early & late stage companies taking novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors

More Info
NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update

Our Approach

New Science Ventures, LLC (NSV) is a Connecticut and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors

Learn More

News

November 10, 2023
NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that the results of the ICONA phase 2b study for the treatment of NASH, will be presented as an oral late-breaker at the AASLD Liver

Read More
November 7, 2023
Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs

Zeotap Data, a leading provider of fully-consented, people-based data solutions, is proud to introduce Validated Demos the key to delivering reach and frequency metrics against your core demographic audience in programmatic media buying. Through exclusive partnerships with Europe’s major mobile telco operators, Zeotap Data employs cutting-edge modelling techniques to leverage

Read More
November 6, 2023
Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a

Read More
October 17, 2023
NorthSea Therapeutics receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the treatment of Intestinal Failure-Associated Liver Disease

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that one of its novel Structural Engineered Fatty Acids (SEFAs), SEFA-6179, has been granted Rare Pediatric Disease (RPD) Designation by the United States Food and

Read More
October 6, 2023
Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier

Glydways, a leader in developing on-demand Personal Rapid Transit (PRT), has announced its $56 million Series B round, including the conversion of notes valued at more than $28 million and led by New Science Ventures with participation from The ACS Group and Gates Frontier. Khosla Ventures, Glydways first investor, is

Read More
September 15, 2023
Paragraf named Business of the Year in Cambridge glory parade

Paragraf, the first company in the world to mass produce graphene-based electronic devices using standard semiconductors processes, was named Business of the Year in the 33rd annual Business Weekly Awards on 14 September 2023. Co-founders Simon Thomas – the CEO – and CSO Professor Sir Colin Humphreys received the coveted

Read More
September 12, 2023
Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform

Zeotap CDP, the easy, secure and impactful Customer Data Platform (CDP) has established a strategic partnership with Artefact, a global data consulting service specialist. This collaboration will help to deliver effective data-driven marketing while prioritising consumer privacy and security. Enterprises will benefit from a holistic and integrated approach that will

Read More
August 15, 2023
VUV Analytics Announces Publication of ASTM D8519-23

VUV Analytics, Inc. is proud to announce the publication of ASTM D8519-23, a groundbreaking new method for the Determination of Hydrocarbon Types in Waste Plastic Process Oil using Gas Chromatography with Vacuum Ultraviolet Absorption Spectroscopy (GC-VUV). This method is the first of its kind, designed to accurately characterize WPPO produced

Read More
June 14, 2023
Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system

Read More
June 7, 2023
Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the

Read More
May 18, 2023
Novadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its

Read More
May 4, 2023
Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections

Trellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, has announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections

Read More
May 2, 2023
Paragraf acquires Cardea Bio to extend graphene electronics leadership

Paragraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become

Read More
February 16, 2023
VUV Analytics announces $20 million financing

VUV Analytics, Inc. has announced that it has raised $20 million in equity financing—led by existing investors S3 Ventures and New Science Ventures—bringing its total funding to over $36 million.  The announcement follows the recent launch of the company’s LUMA product and a record year for revenue with its unit

Read More
February 8, 2023
ProterixBio announces commercial offering of Quantitative Soluble ST2 Assay

ProterixBio, Inc. has announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA cleared for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Heart failure is

Read More
January 31, 2023
Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks

Picocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of

Read More
January 20, 2023
Isorg collaborates with Precise Biometrics on turnkey fingerprint sensor solution for smartphone industry

Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, announces further details on the company’s collaboration with Precise Biometrics, a leader in fingerprint verification software, on a new Fingerprint on Display (FoD) solution for the mobile industry. While increasing resolution unquestionably remains a major trend within the

Read More
January 9, 2023
Isorg’s FAP30 optical fingerprint sensor obtains FBI certification

Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, has announced the FBI certification of Bio1Print30, a large-area optical fingerprint sensor for applications where enhanced mobile security and nomad ID authentication are key. The Bio1Print30, a FAP30 (Fingerprint Acquisition Profile) device, whose core technology is compatible with

Read More
January 5, 2023
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has provided an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment

Read More
December 8, 2022
Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe

Learn More

Contact Us

Greenwich

500 West Putnam Avenue, Suite 400, Greenwich CT 06830
T: 212 688 5100 F: 646 844 9845

London

16 Old Queen Street, London SW1H 9HP
T: 020 3981 9092 F: 020 3981 9100